Aerie Acquires Envisia Technology for $25M to Advance Retinal Program

October 6, 2017: By Jon Swedien

AerieAerie Pharmaceuticals announced Oct. 5 that it has acquired from Envisia Therapeutics the rights to use its PRINT technology in ophthalmology, along with certain other assets.

The PRINT technology is Envisia’s proprietary system for sustained-release products.

Under the terms of the agreement, Envisia will receive $25 million upfront in a combination of cash and Aerie common stock. Envisia, of Durham, North Carolina, could earn more based on certain product approval milestones, Aerie said.

Aerie, of Irvine, California, said it intends to use the technology to accelerate the advancement of its pipeline to treat conditions in the back of the eye, such as wet age-related macular degeneration and diabetic retinopathy.

Aerie’s initial focus will be in using PRINT to manufacture injectable implants containing its preclinical product candidate known as AR-13154, a potential wet AMD treatment.

This potentially could be done in conjunction with a biodegradable polymer from DSM, a Netherlands-based company that Aerie struck a collaborative agreement with in July.

In addition, Aerie acquired the intellectual property rights relating to ENV1105, Envisia’s preclinical dexamethasone steroid product candidate for the treatment of diabetic macular edema, which also uses the PRINT technology, Aerie said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022